Despite the high prevalence of LPR, socioeconomic cost and burden on quality of life, there is currently no effective medical therapy. Pepsin, detected in the airway of patients with LPR and now known to cause inflammation and promote disease independent of gastric acid, is a key therapeutic target.  Our cutting-edge research demonstrates fosamprenavir binds to and inhibits pepsin, preventing pepsin-mediated inflammation and tissue damage. N-Zyme is developing a sustained-release oral formulation of fosamprenavir for the treatment of reflux.  Furthermore, an innovative delivery approach will provide local delivery of a low dose of fosamprenavir direct to the throat. These oral and dry powder inhaler medications will be the first safe, effective, and efficient treatments for the millions of people that suffer from LPR, addressing a significant unmet clinical need.